Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03703557 Recruiting - Breast Cancer Clinical Trials

Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer

KDOG2
Start date: July 25, 2018
Phase: N/A
Study type: Interventional

To ascertain the possibilities to isolate the breast cancer olfactive signature.

NCT ID: NCT03703492 Not yet recruiting - Breast Cancer Clinical Trials

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Start date: October 31, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective, one-arm, observational study which will enroll patients with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care. Eligible patients will be consented for participation in the research study which includes a directed breast PET/MRI with 18F-FES. 18F-FES uptake of the known malignancy will be measured on the PET/MRI examination using standardized uptake values (SUV) and tumor-to-normal tissue ratios.

NCT ID: NCT03703466 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

NCT ID: NCT03702868 Not yet recruiting - Breast Cancer Clinical Trials

Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer

Start date: October 1, 2018
Phase:
Study type: Observational

Breast cancer is the most common cause of cancer death in women. Adjuvant chemotherapy significantly reduces the risk of recurrence of high-risk breast cancer. However, about 30% of patients still have distant metastasis or local recurrence after chemotherapy. Moreover, 60% of patients had 3-4 degrees of adverse drug reactions during chemotherapy. The purpose of the study is to investigate relationship between gut microbiome and adjuvant chemotherapy in early breast cancer patients.

NCT ID: NCT03702712 Not yet recruiting - Breast Cancer Clinical Trials

Responsiveness to Acute Changes in Exercise and Relaxation (RACER) Trial

RACER
Start date: October 15, 2018
Phase: N/A
Study type: Interventional

The purpose of this acute study is to compare the combined effects of aerobic exercise and relaxation training on fatigue and its related cognitive components, among breast cancer survivors. Participants will complete three sessions over a seven-day period in a laboratory setting.

NCT ID: NCT03701334 Not yet recruiting - Early Breast Cancer Clinical Trials

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NATALEE
Start date: December 27, 2018
Phase: Phase 3
Study type: Interventional

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

NCT ID: NCT03698942 Completed - Breast Cancer Clinical Trials

Delphinus SoftVue™ ROC Reader Study

DMT SV RRS
Start date: September 23, 2018
Phase:
Study type: Observational

The purpose of this multi‐reader, multi‐case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in women with dense breast parenchyma. This includes obtaining information that can be used to properly plan, design, and power future ROC reader studies. This reader study will include a minimum of 6 radiologist readers and an enriched sample of at least 100 breast screening or diagnostic cases to be selected from the library of images collected under Delphinus Protocol #DMT‐2015.001 (NCT03257839). The reader study image case set will be enriched with cancer cases.

NCT ID: NCT03698383 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Start date: October 2018
Phase: Phase 2
Study type: Interventional

This study is a multicenter, prospective, single-arm, phase II study to evaluate the antitumor activity and safety of trastuzumab biosimilar (herzuma®) plus gedatolisib in patients with HER-2 positive MBC who progressed after 2 or more HER-2 directed chemotherapy.

NCT ID: NCT03697577 Not yet recruiting - Breast Cancer Clinical Trials

Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer

Start date: December 1, 2018
Phase:
Study type: Observational

The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

NCT ID: NCT03697551 Not yet recruiting - Breast Cancer Clinical Trials

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Start date: October 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions. 68Ga-OPS202 is a radiolabelled imaging agent to be used in association with PET. 68Ga-OPS202 is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium 68, a radioisotope that, combined with OPS202, can be seen in the PET scanner.